-
FRAILTY AND INFLAMMATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING ELECTIVE CARDIAC SURGERY
Mar 18, 2026, 21:38 PM -
REGRESSION-BASED ASSESSMENT OF INCREASED LENGTH OF STAY DUE TO DRPS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS
Mar 18, 2026, 21:38 PM -
EVALUATION OF BARIATRIC SURGERY TRENDS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (2018-2024): REAL WORLD STUDY ASSESSING THE GAP BETWEEN PREVALENCE AND LAPAROSCOPIC UPTAKE
Mar 18, 2026, 21:38 PM -
MEASURING PATIENT-REPORTED DERMATOLOGIC SIDE EFFECTS OF CANCER TREATMENT: PSYCHOMETRIC EVALUATION OF THE SKINDEX-16 IN NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
ASSESSING THE RETURN ON INVESTMENT (ROI) OF HEOR & RWE TO THE BIOPHARMACEUTICAL INDUSTRY: CASE EXAMPLE OF ECONOMIC MODELING IN HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
Mar 18, 2026, 21:38 PM -
A QUALITATIVE STUDY EXAMINING PRO-CTCAE COVERAGE OF TREATMENT-EMERGENT ADVERSE EVENTS REPORTED BY PATIENTS WITH MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM -
ESTIMATING THE MEDICAL UNMET NEED AND BURDEN OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BURDEN OF HIV IN MEXICO: A LIFETIME COST-OF-ILLNESS ANALYSIS
Mar 18, 2026, 21:38 PM -
EVALUATING THE IMPACT OF PHARMACIST-LED DIGITAL AND EDUCATIONAL HEALTH INTERVENTIONS FOR DISEASE AND RISK MANAGEMENT ON ISCHEMIC HEART DISEASE PATIENT
Mar 18, 2026, 21:38 PM -
AN EXPLAINABLE MACHINE LEARNING ANALYSIS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE AND OPIOID-RELATED DIAGNOSIS RISK AMONG ADULT MEDICAID BENEFICIARIES
Mar 18, 2026, 21:38 PM -
PATIENT-CENTERED ENDPOINT STRATEGY FOR BIOLOGIC TRIALS IN SEVERE ASTHMA: INTEGRATING REGULATORY, PAYER, AND PATIENT PRIORITIZED ENDPOINTS
Mar 18, 2026, 21:38 PM -
REAL-WORLD MULTIPLE MYELOMA TREATMENT RESPONSES: EVALUATION OF FRONTLINE REGIMENS IN MELDTM LINKED MEDICARE, LABORATORY AND ELECTRONIC MEDICAL RECORDS...
Mar 18, 2026, 21:38 PM -
REVIEW OF CEESP ICERS FOR ORPHAN AND NON-ORPHAN TREATMENTS IN FRANCE, 2024 - 2025
Mar 18, 2026, 21:38 PM -
GENAI FOR NEXT-GENERATION JCA WORKFLOWS: AUTOMATING EVIDENCE GENERATION WHILE ENSURING TRANSPARENT, TRACEABLE EU-HTA SUBMISSIONS
Mar 18, 2026, 21:38 PM -
NATIONAL TRENDS IN OPIOID, BENZODIAZEPINE AND ANTICHOLINERGIC ORDERS IN LONG-TERM CARE
Mar 18, 2026, 21:38 PM -
HEALTHCARE UTILIZATION PATTERNS AMONG MEDICARE BENEFICIARIES WITH FINANCIAL CONSTRAINTS
Mar 18, 2026, 21:38 PM -
REGULATORY CHALLENGES AND INSIGHTS FROM FDA IN 2025; POTENTIAL IMPLICATIONS OF THE PLAUSIBLE MECHANISM PATHWAY AND SUBSEQUENT HEALTH TECHNOLOGY ASSESSMENTS
Mar 18, 2026, 21:38 PM -
REAL-WORLD EVIDENCE ON AWARENESS, ADOPTION, AND PERCEIVED UTILITY OF PERIOD TRACKING APPLICATIONS FOR MENSTRUAL HEALTH AMONG UNIVERSITY STUDENTS
Mar 18, 2026, 21:38 PM -
REAL-WORLD DATA IN ORPHAN DRUG APPROVALS: A COMPARATIVE ANALYSIS OF THE UNITED STATES, CHINA, AND JAPAN
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB? VERSUS CYCLOSPORINE A IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY
Mar 18, 2026, 21:38 PM
